Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response.

Mollinedo F, Gajate C.

Ann Transl Med. 2019 Jul;7(Suppl 3):S153. doi: 10.21037/atm.2019.06.40. No abstract available.

2.

A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.

Marín-Ramos NI, Balabasquer M, Ortega-Nogales FJ, Torrecillas IR, Gil-Ordóñez A, Marcos-Ramiro B, Aguilar-Garrido P, Cushman I, Romero A, Medrano FJ, Gajate C, Mollinedo F, Philips MR, Campillo M, Gallardo M, Martín-Fontecha M, López-Rodríguez ML, Ortega-Gutiérrez S.

J Med Chem. 2019 Jul 11;62(13):6035-6046. doi: 10.1021/acs.jmedchem.9b00145. Epub 2019 Jun 19.

PMID:
31181882
3.

Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells.

Álvarez R, Gajate C, Puebla P, Mollinedo F, Medarde M, Peláez R.

Eur J Med Chem. 2018 Oct 5;158:167-183. doi: 10.1016/j.ejmech.2018.08.078. Epub 2018 Aug 31.

PMID:
30216850
4.

Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells.

Bello C, Bai J, Zambron BK, Elías-Rodríguez P, Gajate C, Robina I, Caffa I, Cea M, Montecucco F, Nencioni A, Nahimana A, Aubry D, Breton C, Duchosal MA, Mollinedo F, Vogel P.

Eur J Med Chem. 2018 Apr 25;150:457-478. doi: 10.1016/j.ejmech.2018.02.086. Epub 2018 Mar 2.

PMID:
29547833
5.

Antitumor activity of Lepidium latifolium and identification of the epithionitrile 1-cyano-2,3-epithiopropane as its major active component.

Conde-Rioll M, Gajate C, Fernández JJ, Villa-Pulgarin JA, Napolitano JG, Norte M, Mollinedo F.

Mol Carcinog. 2018 Mar;57(3):347-360. doi: 10.1002/mc.22759. Epub 2017 Nov 14.

PMID:
29073716
6.

Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.

Villa-Pulgarín JA, Gajate C, Botet J, Jimenez A, Justies N, Varela-M RE, Cuesta-Marbán Á, Müller I, Modolell M, Revuelta JL, Mollinedo F.

PLoS Negl Trop Dis. 2017 Aug 22;11(8):e0005805. doi: 10.1371/journal.pntd.0005805. eCollection 2017 Aug.

7.

Isolation of Lipid Rafts Through Discontinuous Sucrose Gradient Centrifugation and Fas/CD95 Death Receptor Localization in Raft Fractions.

Gajate C, Mollinedo F.

Methods Mol Biol. 2017;1557:125-138. doi: 10.1007/978-1-4939-6780-3_13. Erratum in: Methods Mol Biol. 2017;1557:E1.

PMID:
28078589
8.

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.

Marín-Ramos NI, Piñar C, Vázquez-Villa H, Martín-Fontecha M, González Á, Canales Á, Algar S, Mayo PP, Jiménez-Barbero J, Gajate C, Mollinedo F, Pardo L, Ortega-Gutiérrez S, Viso A, López-Rodríguez ML.

Chemistry. 2017 Jan 31;23(7):1676-1685. doi: 10.1002/chem.201604905. Epub 2016 Dec 27.

PMID:
27885731
9.

The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death.

Legarda-Ceballos AL, Rojas-Caraballo J, López-Abán J, Ruano AL, Yepes E, Gajate C, Mollinedo F, Muro A.

Acta Trop. 2016 Oct;162:180-187. doi: 10.1016/j.actatropica.2016.07.001. Epub 2016 Jul 6.

PMID:
27394030
10.

Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.

Jaffrès PA, Gajate C, Bouchet AM, Couthon-Gourvès H, Chantôme A, Potier-Cartereau M, Besson P, Bougnoux P, Mollinedo F, Vandier C.

Pharmacol Ther. 2016 Sep;165:114-31. doi: 10.1016/j.pharmthera.2016.06.003. Epub 2016 Jun 8. Review.

PMID:
27288726
11.

Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications.

Gajate C, Mollinedo F.

J Leukoc Biol. 2015 Nov;98(5):739-59. doi: 10.1189/jlb.2MR0215-055R. Epub 2015 Aug 5. Review.

PMID:
26246489
12.

Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine.

Bonilla X, Dakir el-H, Mollinedo F, Gajate C.

Oncotarget. 2015 Jun 10;6(16):14596-613.

13.

Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling.

Gajate C, Mollinedo F.

Apoptosis. 2015 May;20(5):584-606. doi: 10.1007/s10495-015-1104-6. Review.

PMID:
25702154
14.

Triggers and signaling cross-talk controlling cell death commitment.

Melo-Lima S, Gajate C, Mollinedo F.

Cell Cycle. 2015;14(4):465-6. doi: 10.1080/15384101.2015.1006540. No abstract available.

15.

Lipid rafts as major platforms for signaling regulation in cancer.

Mollinedo F, Gajate C.

Adv Biol Regul. 2015 Jan;57:130-46. doi: 10.1016/j.jbior.2014.10.003. Epub 2014 Oct 27. Review.

PMID:
25465296
16.

Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.

Gajate C, Mollinedo F.

Anticancer Agents Med Chem. 2014 May;14(4):509-27. Review.

PMID:
24628241
17.

Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma.

Reis-Sobreiro M, Roué G, Moros A, Gajate C, de la Iglesia-Vicente J, Colomer D, Mollinedo F.

Blood Cancer J. 2013 May 31;3:e118. doi: 10.1038/bcj.2013.15.

18.

Rapid human melanoma cell death induced by sanguinarine through oxidative stress.

Burgeiro A, Bento AC, Gajate C, Oliveira PJ, Mollinedo F.

Eur J Pharmacol. 2013 Apr 5;705(1-3):109-18. doi: 10.1016/j.ejphar.2013.02.035. Epub 2013 Mar 13.

19.

Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast.

Cuesta-Marbán Á, Botet J, Czyz O, Cacharro LM, Gajate C, Hornillos V, Delgado J, Zhang H, Amat-Guerri F, Acuña AU, McMaster CR, Revuelta JL, Zaremberg V, Mollinedo F.

J Biol Chem. 2013 Mar 22;288(12):8405-18. doi: 10.1074/jbc.M112.425769. Epub 2013 Jan 18.

20.

Apoptotic mechanisms are involved in the death of Strongyloides venezuelensis after triggering of nitric oxide.

Ruano AL, López-Abán J, Gajate C, Mollinedo F, De Melo AL, Muro A.

Parasite Immunol. 2012 Dec;34(12):570-80. doi: 10.1111/pim.12004.

21.

Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.

Gajate C, Matos-da-Silva M, Dakir el-H, Fonteriz RI, Alvarez J, Mollinedo F.

Oncogene. 2012 May 24;31(21):2627-39. doi: 10.1038/onc.2011.446. Epub 2011 Nov 7.

PMID:
22056873
22.

Lipid rafts and Fas/CD95 signaling in cancer chemotherapy.

Gajate C, Mollinedo F.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):274-83. doi: 10.2174/157489211796957766. Review.

PMID:
21762074
23.

Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.

Mollinedo F, Fernández M, Hornillos V, Delgado J, Amat-Guerri F, Acuña AU, Nieto-Miguel T, Villa-Pulgarín JA, González-García C, Ceña V, Gajate C.

Cell Death Dis. 2011 May 19;2:e158. doi: 10.1038/cddis.2011.41.

24.

Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells.

Burgeiro A, Gajate C, Dakir el H, Villa-Pulgarín JA, Oliveira PJ, Mollinedo F.

Anticancer Drugs. 2011 Jul;22(6):507-18. doi: 10.1097/CAD.0b013e32834438f6.

PMID:
21527846
25.

Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy.

Mollinedo F, Gajate C.

Future Oncol. 2010 May;6(5):811-21. doi: 10.2217/fon.10.34. Review.

PMID:
20465392
26.

Lipid raft-targeted therapy in multiple myeloma.

Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, Blanco-Prieto MJ.

Oncogene. 2010 Jul 1;29(26):3748-57. doi: 10.1038/onc.2010.131. Epub 2010 Apr 26.

PMID:
20418917
27.

Lipid rafts, death receptors and CASMERs: new insights for cancer therapy.

Mollinedo F, Gajate C.

Future Oncol. 2010 Apr;6(4):491-4. doi: 10.2217/fon.10.22. No abstract available.

28.

In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.

Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, Roué G, Gil J, Colomer D, Campanero MA, Blanco-Prieto MJ.

Clin Cancer Res. 2010 Apr 1;16(7):2046-54. doi: 10.1158/1078-0432.CCR-09-2456. Epub 2010 Mar 16.

29.

Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.

Reis-Sobreiro M, Gajate C, Mollinedo F.

Oncogene. 2009 Sep 10;28(36):3221-34. doi: 10.1038/onc.2009.183. Epub 2009 Jun 29.

PMID:
19561642
30.

Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.

Gajate C, Gonzalez-Camacho F, Mollinedo F.

PLoS One. 2009;4(4):e5044. doi: 10.1371/journal.pone.0005044. Epub 2009 Apr 7.

31.

Lipid raft connection between extrinsic and intrinsic apoptotic pathways.

Gajate C, Gonzalez-Camacho F, Mollinedo F.

Biochem Biophys Res Commun. 2009 Mar 20;380(4):780-4. doi: 10.1016/j.bbrc.2009.01.147. Epub 2009 Jan 29.

PMID:
19338752
32.

Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis.

Mollinedo F, Gajate C, Morales AI, del Canto-Jañez E, Justies N, Collía F, Rivas JV, Modolell M, Iglesias A.

J Pharmacol Exp Ther. 2009 May;329(2):439-49. doi: 10.1124/jpet.108.148254. Epub 2009 Feb 25.

PMID:
19244550
33.

Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.

Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ.

Clin Cancer Res. 2009 Feb 1;15(3):858-64. doi: 10.1158/1078-0432.CCR-08-1654.

34.

Edelfosine is incorporated into rafts and alters their organization.

Ausili A, Torrecillas A, Aranda FJ, Mollinedo F, Gajate C, Corbalán-García S, de Godos A, Gómez-Fernández JC.

J Phys Chem B. 2008 Sep 18;112(37):11643-54. doi: 10.1021/jp802165n. Epub 2008 Aug 20.

PMID:
18712919
35.

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.

Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC.

Cancer Res. 2008 Jul 1;68(13):5216-25. doi: 10.1158/0008-5472.CAN-07-5725.

36.

Differential gene expression patterns coupled to commitment and acquisition of phenotypic hallmarks during neutrophil differentiation of human leukaemia HL-60 cells.

Mollinedo F, López-Pérez R, Gajate C.

Gene. 2008 Aug 1;419(1-2):16-26. doi: 10.1016/j.gene.2008.04.015. Epub 2008 May 6.

PMID:
18547747
37.

Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells.

Nieto-Miguel T, Fonteriz RI, Vay L, Gajate C, López-Hernández S, Mollinedo F.

Cancer Res. 2007 Nov 1;67(21):10368-78.

38.

Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.

Nieto-Miguel T, Gajate C, González-Camacho F, Mollinedo F.

Oncogene. 2008 Mar 13;27(12):1779-87. Epub 2007 Sep 24.

PMID:
17891170
39.

Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells.

Zhang H, Gajate C, Yu LP, Fang YX, Mollinedo F.

Acta Pharmacol Sin. 2007 Jun;28(6):888-94.

41.

Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils.

Mollinedo F, Calafat J, Janssen H, Martín-Martín B, Canchado J, Nabokina SM, Gajate C.

J Immunol. 2006 Sep 1;177(5):2831-41.

42.

Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.

Mollinedo F, Gajate C.

Drug Resist Updat. 2006 Feb-Apr;9(1-2):51-73. Epub 2006 May 9. Review.

PMID:
16687251
43.

Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes.

Torrecillas A, Aroca-Aguilar JD, Aranda FJ, Gajate C, Mollinedo F, Corbalán-García S, de Godos A, Gómez-Fernández JC.

Int J Pharm. 2006 Aug 2;318(1-2):28-40. Epub 2006 Mar 17.

PMID:
16624506
44.

Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.

Nieto-Miguel T, Gajate C, Mollinedo F.

J Biol Chem. 2006 May 26;281(21):14833-40. Epub 2006 Mar 15.

45.

DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.

David-Cordonnier MH, Gajate C, Olmea O, Laine W, de la Iglesia-Vicente J, Perez C, Cuevas C, Otero G, Manzanares I, Bailly C, Mollinedo F.

Chem Biol. 2005 Nov;12(11):1201-10.

46.

Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition.

Zaremberg V, Gajate C, Cacharro LM, Mollinedo F, McMaster CR.

J Biol Chem. 2005 Nov 11;280(45):38047-58. Epub 2005 Sep 9.

47.
48.

Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety.

Maya AB, Pérez-Melero C, Mateo C, Alonso D, Fernández JL, Gajate C, Mollinedo F, Peláez R, Caballero E, Medarde M.

J Med Chem. 2005 Jan 27;48(2):556-68.

PMID:
15658869
49.

ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.

Mollinedo F, Gajate C, Martín-Santamaría S, Gago F.

Curr Med Chem. 2004 Dec;11(24):3163-84. Review.

PMID:
15579006
50.

Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells.

Quesada E, Delgado J, Gajate C, Mollinedo F, Acuña AU, Amat-Guerri F.

J Med Chem. 2004 Oct 21;47(22):5333-5.

PMID:
15481970

Supplemental Content

Loading ...
Support Center